绿新生物科技发盈警 预期上半年公司拥有人应占亏损净额约1100万-1350万元 同比盈转亏

Core Viewpoint - The company expects to report a net loss attributable to shareholders of approximately RMB 11 million to 13.5 million in the first half of 2025, compared to a net profit of RMB 23.08 million in the same period of 2024 [1] Group 1: Financial Performance - The anticipated decline in performance is primarily due to a decrease in both the selling price and sales volume of the company's main hydrophilic colloid products, leading to reduced revenue and gross profit during the reporting period [1] - The company has increased its research and development expenditures related to the technology and knowledge for current mainstream products and new products during the reporting period [1]